文献速递糖尿病

德谷胰岛素/利拉鲁肽对比每日多次胰岛素注射在住院转门诊中的DELI transition试验

Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial.
PubMed 文献 · Diabetologia · 2025-08-04

主要结局显示IDegLira组发生至少一次低血糖事件(血糖<3.0 mmol/l)的比例为6.2%,低于MDI组的31.3%(p<0.010),且IDegLira组TIR 3.8-10 mmol/l更高(80.6% vs 69.7%,p=0.008)。结论认为IDegLira在住院转门诊过程中比MDI更安全有效。

要点

  • IDegLira组低血糖事件比例6.2%,显著低于MDI组31.3%(p<0.010)。
  • IDegLira组TIR 3.8-10 mmol/l为80.6%,高于MDI组69.7%(p=0.008)。
  • IDegLira组TBR<3.8 mmol/l和<3.0 mmol/l均低于MDI组。

核心结论

  • 对于血糖控制欠佳的2型糖尿病患者,从住院过渡到门诊时使用IDegLira比MDI更安全且更有效。

研究设计与样本

  • 基线HbA1c为103 ± 11.6 mmol/mol(11.6 ± 1.7%),年龄58 ± 12.4岁(均值±标准差)。

主要发现

  • IDegLira组发生至少一次低血糖事件(血糖<3.0 mmol/l)的比例为6.2%,MDI组为31.3%(p<0.010)。
  • 低血糖事件密度 incidence rate ratio 为15.2(95% CI 6.2, 48.2;p<0.001)。
  • TBR<3.8 mmol/l为0.9% vs 2.9%(p=0.019),TBR<3.0 mmol/l为0.6% vs 1.3%(p=0.008)。
  • TIR 3.8-10 mmol/l为80.6% vs 69.7%(p=0.008)。
  • 无论基线HbA1c如何,结果一致。

关键数值与推荐

  • 主要安全性结局定义为随访前4周内连续血糖监测记录到至少一次血糖<3.0 mmol/l且持续超过15分钟的低血糖事件患者百分比。

临床怎么用

  • 对于住院期间血糖控制欠佳、计划出院的2型糖尿病患者,可考虑使用IDegLira替代MDI以降低低血糖风险并提高TIR。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/OBJECTIVE: The aim of the study was to assess the safety profile (defined as the percentage of patients with at least one hypoglycaemic event [more than 15 min with glucose levels <3.0 mmol/l as documented by continuous glucose monitoring] in the first 4 weeks of follow-up) for insulin degludec/liraglutide (IDegLira) compared with multiple daily insulin injections (MDI) during the transition from hospital to an outpatient setting. METHODS: The study was an open-label, randomised, controlled clinical trial comparing IDegLira to MDI after hospital discharge in patients with type 2 diabetes. The study evaluated the percentage of patients with at least one hypoglycaemic event, the hypoglycaemia event density, the time in range (TIR 3.8-10 mmol/l), the time below range (TBR <3.0 or <3.8 mmol/l), and other glycaemic management metrics measured by continuous glucose monitoring. RESULTS: Sixty-four patients were included in the analysis (32 in each group). They had a baseline HbA1c of 103 ± 11.6 mmol/mol (11.6 ± 1.7%) and age of 58 ± 12.4 years (means ± SD). The proportion of patients with at least one hypoglycaemic event (plasma glucose <3.0 mmol/l) was lower in the IDegLira group than in the MDI group (6.2% vs 31.3%; p<0.010), as was the hypoglycaemia event density (incidence rate ratio 15.2; 95% CI 6.2, 48.2; p<0.001), TBR <3.8 mmol/l (0.9% vs 2.9%; p=0.019) and TBR <3.0 mmol/l (0.6% vs 1.3%, p=0.008). The TIR 3.8-10 mmol/l was higher in the IDegLira group (80.6% vs 69.7%; p=0.008). The findings were consistent regardless of baseline HbA1c. CONCLUSIONS/INTERPRETATION: IDegLira proved to be safer and more effective than MDI for individuals with type 2 diabetes who had suboptimal glycaemic control, aiding in their transition from hospital to outpatient care. TRIAL REGISTRATION: Clinicaltrials.gov NCT05767255 FUNDING: This research was funded by a grant from the Asociación Colombiana de Endocrinología, Diabetes y Metabolismo (ACE).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Gómez-Medina AM, Henao-Carillo DC, Villamil-Castañeda LP, et al. Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial. Diabetologia. 2025. PMID: 40760249. doi:10.1007/s00125-025-06446-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。